Anti-Amyloid Therapies for Alzheimer’s Disease: An Alzheimer Europe Position Paper and Call to Action

Angela C. Bradshaw,J. Georges,A.C. Bradshaw

DOI: https://doi.org/10.14283/jpad.2024.37

2024-01-01

Abstract:The growing prevalence and burden of Alzheimer’s disease has catalysed huge investments in research on its causes, diagnosis, treatment and care. After many high-profile failures, recent clinical trials of anti-amyloid drugs have marked a turning point for the field, leading to the approval of the first disease-modifying therapies for Alzheimer’s disease by the FDA. It is now up to European regulators to determine whether there is sufficient evidence to approve these drugs for patients with mild cognitive impairment or mild dementia due to Alzheimer’s disease. Here, we outline Alzheimer Europe’s position on anti-amyloid therapies for Alzheimer’s disease, which was adopted by the Board of Alzheimer Europe following consultations with our member associations and with the European Working Group of People with Dementia. Beyond questions of drug efficacy, safety and cost, we highlight important issues that must be addressed by industry, regulators, payers, healthcare systems and governments, to ensure that patients have timely, appropriate and equitable access to innovative treatments, regardless of their socio-economic background, insurance status, or place of residence. We also call for continued investment in research on treatments that might benefit people with more advanced Alzheimer’s disease–as well as support and care services that can help people live well with dementia at all stages of the disease.

clinical neurology

What problem does this paper attempt to address?

The paper primarily explores issues related to anti-amyloid therapies for Alzheimer's disease (AD) and proposes a series of calls to action for the industry, regulatory agencies, payers, healthcare systems, and governments. Specifically, the paper aims to address the following key issues:

1. **Approval and Accessibility of Anti-Amyloid Drugs**: With the U.S. Food and Drug Administration (FDA) approving several anti-amyloid drugs (such as aducanumab and lecanemab), European regulatory agencies face the decision challenge of whether to also approve these drugs for patients with mild cognitive impairment or mild Alzheimer's disease.

2. **Importance of Communicating Drug Benefits and Risks**: Given that anti-amyloid drugs have the potential to slow disease progression but also come with certain side effects (such as brain edema and microhemorrhages), the paper emphasizes the importance of clearly and transparently communicating the benefits and risks of these drugs to patients and their caregivers to help them make informed choices.

3. **Ensuring Timely and Accurate Diagnosis**: Since the target population for anti-amyloid drugs is typically limited to those in the mild cognitive impairment or mild Alzheimer's disease stages and requires confirmation of amyloid pathology through biomarkers, ensuring the timeliness and accuracy of early diagnosis is crucial. This not only concerns the accessibility of treatment but also whether patients can benefit from the therapy.

4. **Preparation and Investment in Healthcare Systems**: To ensure that anti-amyloid drugs can be widely and equitably accessed, healthcare systems need to be well-prepared. This includes, but is not limited to, enhancing diagnostic capabilities, establishing biomarker assessment processes, expanding the workforce of specialists, and ensuring the necessary infrastructure is in place.

In summary, the goal of the paper is to promote understanding and acceptance of anti-amyloid therapies and to call on relevant parties to take action to ensure these innovative therapies can receive appropriate approval, timely access, and equitable distribution in Europe.